Time on treatment analysis demonstrated that every year on interferon reduced the risk of progression to myelofibrosis (MF) by 9% (HR 0.91 [95% CI, 0.87–0.95]; p < 0.001), and was associated with a mortality risk reduction by 6% per year (HR 0.94 [95% CI, 0.90–0.99]; p < 0.012). Discontinuation rates were similar between IFN (2.2/100 patient-years) and HU (2.8/100 patient-years)
Furthermore, IFN was also shown to reduce the risk of Myelofibrosis compared with HU and Phlebotomy